<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Candida osteoarticular infections</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Candida osteoarticular infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Candida osteoarticular infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jose A Vazquez, MD, FACP, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Invasive <em>Candida</em> infections tend to occur in selected patients, including those who are immunocompromised (eg, neutropenia, glucocorticoid therapy), have indwelling central venous catheters, have received broad-spectrum antibiotics, or who inject drugs [<a href="#rid1">1,2</a>]. <em>Candida albicans</em> is the most common pathogen, but other species, such as <em>Candida glabrata</em>, <em>Candida parapsilosis</em>, and <em>Candida tropicalis</em>, can be involved [<a href="#rid2">2-8</a>].</p><p>Clinical issues related to <em>Candida</em> osteomyelitis and arthritis will be reviewed here. An overview of <em>Candida</em> infections is presented separately. (See  <a class="medical medical_review" href="/z/d/html/2416.html" rel="external">"Overview of Candida infections"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISMS AND SITES OF INFECTION</span><span class="headingEndMark"> — </span><em>Candida</em> osteoarticular infections are most often due to hematogenous seeding of the joint or bone in patients who have been candidemic [<a href="#rid1">1,2,8-12</a>]. The areas most often seeded during an episode of candidemia in adults are intervertebral discs and knee joints [<a href="#rid2">2,10,11</a>].</p><p>Exogenous inoculation also can lead to infection in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>After trauma or at the time of intraarticular injection (most often the knee) or prosthesis implantation [<a href="#rid9">9,13,14</a>]. (See  <a class="medical medical_review" href="/z/d/html/7659.html" rel="external">"Osteomyelitis associated with open fractures in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After surgical procedures, such as median sternotomy for heart surgery [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/2436.html" rel="external">"Candida infections of the abdomen and thorax", section on 'Mediastinitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In people who inject drugs, especially those who use brown heroin [<a href="#rid16">16</a>]. These patients may develop a unique syndrome consisting of septic arthritis (usually costochondral or sternoclavicular), endophthalmitis, and folliculitis involving the face, scalp, and chest.</p><p></p><p>Among patients with osteomyelitis, the site of involvement varies with age. The vertebrae are most commonly involved in adults [<a href="#rid2">2,8,11,17-20</a>], whereas the long bones of the extremities are more likely to be involved in children [<a href="#rid8">8,21</a>]. Of 207 cases of <em>Candida</em> osteomyelitis in adults and children, the most common sites of infection were the vertebra (in 51 percent), the femur (in 14 percent), the ribs (in 13 percent), and the sternum (in 11 percent) [<a href="#rid8">8</a>].</p><p>Among patients with septic arthritis, most infections have been described in native joints, but prosthetic joints can also be involved [<a href="#rid13">13,22</a>]. In a review of 112 patients (of whom 31 percent were children) with non-prosthetic joint <em>Candida</em> arthritis, the knee was involved in 75 percent of cases [<a href="#rid23">23</a>]. Approximately one-third of cases involved more than one joint, and another third were associated with adjacent osteomyelitis. Most were related to hematogenous dissemination, but 19 percent were thought to be due to direct inoculation.</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Osteoarticular infections often become symptomatic weeks or months after an episode of candidemia or a surgical procedure, and the manifestations are generally more subtle than bacterial infections at the same sites. Both of these factors contribute to long delays in diagnosis, especially in patients with vertebral osteomyelitis [<a href="#rid1">1,2,8-11</a>].</p><p>The most common symptom of <em>Candida</em> osteomyelitis is local pain [<a href="#rid2">2,8,10</a>], and some patients also have tenderness, erythema, and edema [<a href="#rid8">8</a>]. Fever is present in less than one-third of patients [<a href="#rid2">2,8</a>]. Limitation of function and movement occurs in nearly one-third of patients [<a href="#rid8">8</a>]. Sinus tracts and purulent drainage occur in 32 percent of patients with non-vertebral osteomyelitis but in only 1 percent of patients with vertebral osteomyelitis.</p><p>In a literature review of 59 patients with <em>Candida</em> vertebral osteomyelitis, most patients (83 percent) had back pain for more than one month, and 29 percent had back pain for more than three months [<a href="#rid2">2</a>]. The primary site of involvement was the lower thoracic or lumbar spine in almost all patients. Approximately 20 percent had neurologic deficits.</p><p>Similar findings were noted in another review of 65 patients with <em>Candida</em> vertebral osteomyelitis [<a href="#rid11">11</a>]. Among the 40 patients with documented candidemia before the onset of osteomyelitis, the delay between the detection of candidemia and the onset of symptoms was 2 to 12 months in 70 percent and more than one year in 10 percent.</p><p>When a joint is infected, the major symptoms are pain, swelling, erythema, and decreased range of motion. (See  <a class="medical medical_review" href="/z/d/html/7666.html" rel="external">"Septic arthritis in adults", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/7664.html" rel="external">"Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A high index of suspicion is required to establish the diagnosis of <em>Candida</em> osteoarticular infections [<a href="#rid2">2,11</a>]. Two clinical clues are a history of or current or recent detection of candidemia and the presence of risk factors for <em>Candida</em> infection [<a href="#rid2">2,8,11</a>]. Among 207 patients with <em>Candida</em> osteomyelitis, 57 (28 percent) had preceding candidemia, and 31 (15 percent) had candidemia at the time of diagnosis with <em>Candida</em> osteomyelitis [<a href="#rid8">8</a>]. Among 112 patients with <em>Candida</em> arthritis, 63 percent had candidemia or other forms of candidiasis; however, only 11 percent were candidemic at the time the diagnosis of septic arthritis was made [<a href="#rid23">23</a>].</p><p>In a review of 65 patients with vertebral osteomyelitis, all but three had at least one risk factor, and the median number of risk factors was three in patients with candidemia [<a href="#rid11">11</a>]. The most frequent risk factors were the use of broad-spectrum antibiotics and central venous catheters.</p><p>In <em>Candida </em>osteoarticular infections, the erythrocyte sedimentation rate and C-reactive protein are usually elevated; the white blood cell count is often normal or only mildly elevated [<a href="#rid8">8</a>].</p><p>Among imaging studies in patients with osteomyelitis, plain radiography can show erosive and destructive changes, but these changes may not be visible upon presentation and frequently take weeks to be visible on plain radiography. Magnetic resonance imaging (MRI) is the imaging modality of choice, as it is in bacterial osteomyelitis. In a study of 207 patients with <em>Candida </em>osteomyelitis, MRI findings included decreased signal intensity on T1-weighted images, increased signal intensity on contrast-enhanced T1-weighted images, and increased signal intensity on T2-weighted images [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">"Vertebral osteomyelitis and discitis in adults"</a>.)</p><p>The definitive diagnosis is established by culture of the infected site. <em>Candida</em> arthritis is more easily confirmed than osteomyelitis because synovial fluid can be readily obtained for culture. <em>Candida</em> species usually grow in a few days when plated on standard media, such as sheep's blood agar, or on Sabouraud dextrose agar. It is important to point out that even a single colony of <em>Candida</em> spp recovered from joint fluid, a bone biopsy, or an aspirate should be viewed as significant and pathogenic, and the patient should be treated with antifungal agents as described below.</p><p>Culture of <em>Candida</em> species from a chronic draining wound, as often occurs with <em>Candida</em> sternal osteomyelitis or a chronic diabetic foot infection, is frequently disregarded as skin microbiota. However, repeated isolation of <em>Candida</em> and no other pathogen makes it possible that <em>Candida</em> is the causative agent [<a href="#rid15">15</a>]. In these cases, it is imperative to submit tissue for both microbiologic workup and histopathologic workup with appropriate stains.</p><p class="headingAnchor" id="H5"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span><em>Candida</em> septic arthritis in a native joint is easier to treat than osteomyelitis because adequate antifungal drug levels are more easily achieved in synovial fluid than in bone [<a href="#rid1">1,13,21,24,25</a>].</p><p>Fungal prosthetic joint infections are difficult to cure with medical therapy alone. Most patients with prosthetic joint infections require prosthesis removal followed by an extended course of antifungal therapy to resolve their infections. (See  <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment"</a>.)</p><p>Osteomyelitis is difficult to treat because the diagnosis is often delayed for weeks to months [<a href="#rid2">2,11</a>], the infected bone is often poorly perfused (which limits both the host inflammatory response and the delivery of antifungal drugs), and there may be foreign material present, as occurs with median sternotomy. Few data are available on the penetration of antifungal agents into bone [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Septic arthritis</span></p><p class="headingAnchor" id="H2159495382"><span class="h3">Native joint</span><span class="headingEndMark"> — </span>Adequate drainage and source control is essential for the treatment of all cases of <em>Candida </em>septic arthritis [<a href="#rid27">27</a>]. In one review of a large number of cases, 36 percent were treated with both surgical debridement and antifungal agents, but 62 percent were treated with only antifungal agents.</p><p>Antifungal treatment recommendations for septic arthritis caused by fluconazole-susceptible <em>Candida</em> species, such as <em>C. albicans</em>, <em>C. parapsilosis</em>, and <em>C. tropicalis</em> include oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg [6 mg/kg]) daily for at least six weeks or an intravenous (IV) echinocandin daily for at least two weeks, followed by oral fluconazole (400 mg [6 mg/kg]) daily for at least four weeks (<a class="graphic graphic_table graphicRef87679" href="/z/d/graphic/87679.html" rel="external">table 1</a>) [<a href="#rid27">27</a>]. Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients. IV therapy with either an echinocandin or fluconazole (at the same dose as the oral dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill. Patients treated initially with IV fluconazole should be transitioned to oral fluconazole when feasible.</p><p>The doses of the echinocandins that we suggest for septic arthritis are:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">Caspofungin</a> – 70 mg IV (loading dose), followed by 50 to 70 mg IV daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">Anidulafungin</a> – 200 mg IV (loading dose), followed by 100 mg IV daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">Micafungin</a> – 100 mg IV daily</p><p></p><p>Alternatively, a lipid formulation of amphotericin B, 3 to 5 mg/kg IV daily for two weeks, followed by oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg [6 mg/kg]) for at least four weeks, can also be given if echinocandins are not available. This regimen is a less attractive alternative to the first-line regimens because of the nephrotoxicity of amphotericin B formulations. Case reports have described cures in patients treated with fluconazole, <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">caspofungin</a>, or amphotericin B in combination with adequate source control [<a href="#rid27">27-30</a>].</p><p>Instillation of amphotericin B into the joint space has been described. However, it is <strong>not</strong> recommended because drug levels are adequate with systemic therapy and irritation of synovial tissues is common with intraarticular therapy.</p><p class="headingAnchor" id="H7"><span class="h3">Prosthetic joint infections</span><span class="headingEndMark"> — </span>In addition to antifungal drugs, the cure of prosthetic joint infections almost always requires removal of all prosthetic material. The preferred approach is a two-stage procedure in which the infected prosthesis is removed, followed by antifungal therapy, and a new prosthesis is implanted three to six months later. Antifungal therapy should be continued for at least 12 weeks after the resection arthroplasty and for at least 6 weeks after the prosthesis has been replaced [<a href="#rid22">22,27,31-33</a>].</p><p>Although cures have been described with debridement without removal of the prosthesis [<a href="#rid13">13,14,34,35</a>], this approach is not recommended for most patients with fungal infections. If the prosthetic device cannot be removed, chronic suppression with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 400 mg (6 mg/kg) orally daily should be given if the isolate is susceptible [<a href="#rid27">27</a>].</p><p>Treatment of infections caused by fluconazole-resistant <em>Candida</em> isolates is discussed below. (See <a class="local">'Candida glabrata'</a> below and <a class="local">'Other Candida species'</a> below.)</p><p>Treatment of prosthetic joint infections is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Osteomyelitis</span><span class="headingEndMark"> — </span>Treatment recommendations for osteomyelitis caused by fluconazole-susceptible <em>Candida </em>species, such as <em>C. albicans,</em> include oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg [6 mg/kg]) daily for 6 to 12 months <strong>or</strong> an IV echinocandin daily for at least 2 weeks followed by oral fluconazole (400 mg [6 mg/kg]) for a total of 6 to 12 months (<a class="graphic graphic_table graphicRef87679" href="/z/d/graphic/87679.html" rel="external">table 1</a>) [<a href="#rid27">27</a>]. Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients. IV therapy with an echinocandin or fluconazole (at the same dose as the oral dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill. Patients treated initially with IV fluconazole should be transitioned to oral fluconazole when feasible.</p><p>The doses of the echinocandins that we suggest for osteomyelitis are:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">Caspofungin</a> – 70 mg IV (loading dose), followed by 50 to 70 mg IV daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">Anidulafungin</a> – 200 mg IV (loading dose), followed by 100 mg IV daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">Micafungin</a> – 100 mg IV daily</p><p></p><p>Alternatively, a lipid formulation of amphotericin B, 3 to 5 mg/kg IV daily, can be given for at least 2 weeks followed by oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg [6 mg/kg]) for 6 to 12 months. This regimen is a less attractive alternative than the first-line regimens because of the nephrotoxicity of amphotericin B formulations. Treatment of infections caused by fluconazole-resistant <em>Candida</em> isolates is discussed below. (See <a class="local">'Candida glabrata'</a> below and <a class="local">'Other Candida species'</a> below.)</p><p>There are no formal clinical trials, so treatment recommendations are based upon case reports and case series [<a href="#rid27">27</a>]. Although most case reports and clinical experience have utilized <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, several reports currently support the use of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or an echinocandin as the preferred first-line agents [<a href="#rid8">8,15,19,20,36-39</a>].</p><p>Surgical debridement plays an important role in the treatment of <em>Candida</em> osteomyelitis involving non-vertebral sites, but the role of surgical debridement for vertebral osteomyelitis is less clear. Most authors note efficacy with antifungal therapy alone [<a href="#rid2">2,10,36,40</a>], although some favor debridement [<a href="#rid11">11</a>]. Surgery is clearly indicated if there is an associated epidural abscess, neurologic compromise, or instability of the spine. (See  <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">"Vertebral osteomyelitis and discitis in adults"</a>.)</p><p>In a review of 207 cases of <em>Candida</em> osteomyelitis that were reported between 1970 and 2011, 44 percent were treated with antifungal therapy alone, 5 percent with surgery alone, and 48 percent with antifungal therapy in combination with surgery [<a href="#rid8">8</a>]. Among the 92 patients treated with antifungal agents alone, 97 percent had a favorable response, but 16 (17 percent) relapsed. Among the 100 patients who had both antifungal treatment and surgery, 90 percent responded, but the relapse rate was 43 percent. However, without detailed information regarding the type of antifungal drug used and the duration of treatment, it is difficult to know why the relapse rates were so high, especially for the group who received combined medical and surgical therapy. The authors suggested that many patients relapsed because the duration of therapy was too short.</p><p class="headingAnchor" id="H520647194"><span class="h1">ANTIFUNGAL THERAPY BASED ON SPECIES</span></p><p class="headingAnchor" id="H520647031"><span class="h2">Candida albicans</span><span class="headingEndMark"> — </span>The majority of <em>C. albicans</em> isolates are susceptible to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and the echinocandins. Specific treatment recommendations are presented above. (See <a class="local">'Treatment'</a> above.)</p><p class="headingAnchor" id="H10"><span class="h2">Candida glabrata</span><span class="headingEndMark"> — </span>The choice of therapy with <em>C. glabrata</em> osteoarticular infections is more limited than with <em>C. albicans</em> [<a href="#rid2">2-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Because many isolates of <em>C. glabrata</em> are resistant to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, this agent should <strong>not</strong> be used initially for the treatment of <em>C. glabrata</em> osteoarticular infections. It is essential to obtain susceptibilities prior to switching to either fluconazole or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echinocandins are the initial agents of choice for osteoarticular infections due to <em>C. glabrata</em>, followed by step-down therapy with oral azoles (<a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>) if the isolate is susceptible [<a href="#rid37">37,41,42</a>]. It is essential to obtain susceptibilities before using voriconazole because of the common occurrence of cross-resistance with fluconazole. (See  <a class="medical medical_review" href="/z/d/html/465.html" rel="external">"Antifungal susceptibility testing"</a> and  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The greatest experience in treating <em>C. glabrata</em> osteoarticular infections is with amphotericin B [<a href="#rid2">2-5</a>]. However, echinocandins are less toxic and are preferred as initial therapy. Echinocandins should be given for at least two weeks, followed by an azole (if the isolate is susceptible) for 6 to 12 months. If the isolate is resistant to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, in vitro susceptibilities to <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> and <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a> can be obtained. Although clinical data for these two azoles is lacking, they are oral options that may be used as alternatives to the parenteral alternatives of either an echinocandin or amphotericin B. The other option would be to continue with parenteral echinocandin or amphotericin B for the entire treatment period.</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Other Candida species</span><span class="headingEndMark"> — </span><em>Candida krusei</em> is resistant to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, but most isolates are susceptible to <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, echinocandins, and amphotericin B. Only a small number of case reports are available showing benefit from voriconazole alone [<a href="#rid43">43</a>] or <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">caspofungin</a> with voriconazole [<a href="#rid42">42</a>] in treating osteoarticular infection due to <em>C. krusei</em>. For most patients, echinocandins or a lipid formulation of amphotericin B are the agents of first choice, followed by step-down therapy to voriconazole after improvement is noted. (See  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p><em>C. parapsilosis</em> isolates may be less susceptible to echinocandins than other <em>Candida</em> species. The clinical implications of these higher minimum inhibitory concentration values are not clear, but we prefer <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> for the treatment of osteoarticular infections due to this species. (See  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p>For other <em>Candida </em>species, antifungal susceptibility tests should be performed to help guide appropriate therapy. (See  <a class="medical medical_review" href="/z/d/html/465.html" rel="external">"Antifungal susceptibility testing"</a>.)</p><p class="headingAnchor" id="H1611480404"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a>.)</p><p class="headingAnchor" id="H3559292"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Invasive <em>Candida</em> infections tend to occur in selected patients, including those who are immunocompromised (eg, neutropenia, glucocorticoid therapy), have indwelling central venous catheters, have received broad-spectrum antibiotics, or those who inject drugs. <em>Candida albicans</em> is the most common pathogen, but other species, such as <em>C. glabrata</em>, <em>C. parapsilosis</em>, and <em>C. tropicalis</em>, can be involved. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis and anatomic sites</strong> – <em>Candida</em> osteoarticular infections are most often due to hematogenous seeding of the joint or bone in patients who have been candidemic. The areas most often seeded during an episode of candidemia in adults are intervertebral discs and knee joints. Exogenous inoculation also can lead to infections after trauma, surgical procedures, or intraarticular injections. (See <a class="local">'Mechanisms and sites of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Osteoarticular infections often become symptomatic months after an episode of candidemia or a surgical procedure, and the manifestations are generally more subtle than bacterial infections at the same sites. Both of these factors contribute to long delays in diagnosis, especially in patients with vertebral osteomyelitis. The most common symptom of <em>Candida</em> osteomyelitis is local pain. When a joint is infected, the major symptoms are pain and decreased range of motion. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A high index of suspicion is required to establish the diagnosis of <em>Candida</em> osteoarticular infections because the clinical, laboratory, and radiologic findings are not specific. The diagnosis is established by culture of the infected site. Even a single colony of <em>Candida</em> on culture of joint fluid or bone biopsy or aspirate should be viewed as pathogenic, and the patient should be treated with antifungal agents. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Septic arthritis</strong> – Adequate drainage is essential for the treatment of all cases of <em>Candida</em> septic arthritis. (See <a class="local">'Septic arthritis'</a> above.)</p><p></p><p class="bulletIndent1">Antifungal treatment recommendations for septic arthritis include oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> daily for at least six weeks <strong>or</strong> an intravenous (IV) echinocandin daily for at least 2 weeks, followed by oral fluconazole daily for at least 4 weeks (<a class="graphic graphic_table graphicRef87679" href="/z/d/graphic/87679.html" rel="external">table 1</a>). Antifungal regimens for non-albicans <em>Candida</em> infections are discussed above. (See <a class="local">'Septic arthritis'</a> above and <a class="local">'Candida glabrata'</a> above and <a class="local">'Other Candida species'</a> above.)</p><p></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prosthetic joint infections</strong> – In addition to antifungal drugs, the cure of prosthetic joint infections almost always requires removal of all prosthetic material. (See <a class="local">'Prosthetic joint infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteomyelitis</strong> – Treatment recommendations for osteomyelitis include oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> daily for 6 to 12 months <strong>or</strong> an IV echinocandin daily for at least 2 weeks followed by oral fluconazole for 6 to 12 months (<a class="graphic graphic_table graphicRef87679" href="/z/d/graphic/87679.html" rel="external">table 1</a>). (See <a class="local">'Osteomyelitis'</a> above.)</p><p></p><p class="bulletIndent1">Surgical debridement plays an important role in the treatment of <em>Candida</em> osteomyelitis involving non-vertebral sites, but the role of surgical debridement for vertebral osteomyelitis is less clear. Most authors note efficacy with antifungal therapy alone although some favor debridement. Surgery is clearly indicated if there is an associated epidural abscess, neurological compromise, or instability of the spine. (See <a class="local">'Osteomyelitis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Johnson MD, Perfect JR. Fungal Infections of the Bones and Joints. Curr Infect Dis Rep 2001; 3:450.</a></li><li><a class="nounderline abstract_t">Miller DJ, Mejicano GC. Vertebral osteomyelitis due to Candida species: case report and literature review. Clin Infect Dis 2001; 33:523.</a></li><li><a class="nounderline abstract_t">Ramamohan N, Zeineh N, Grigoris P, Butcher I. Candida glabrata infection after total hip arthroplasty. J Infect 2001; 42:74.</a></li><li><a class="nounderline abstract_t">Zmierczak H, Goemaere S, Mielants H, et al. Candida glabrata arthritis: case report and review of the literature of Candida arthritis. Clin Rheumatol 1999; 18:406.</a></li><li><a class="nounderline abstract_t">Gunthard HF, Meltzer H, Karpinski NC, Ziegler EJ . Spinal osteomyelitis caused by Candida glabrata: case report and review. Infect Dis Clin Pract 1998; 7:12.</a></li><li><a class="nounderline abstract_t">Ferra C, Doebbeling BN, Hollis RJ, et al. Candida tropicalis vertebral osteomyelitis: a late sequela of fungemia. Clin Infect Dis 1994; 19:697.</a></li><li><a class="nounderline abstract_t">Weers-Pothoff G, Havermans JF, Kamphuis J, et al. Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature. Infection 1997; 25:109.</a></li><li><a class="nounderline abstract_t">Gamaletsou MN, Kontoyiannis DP, Sipsas NV, et al. Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). Clin Infect Dis 2012; 55:1338.</a></li><li><a class="nounderline abstract_t">Cuéllar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis 1992; 51:690.</a></li><li><a class="nounderline abstract_t">Gathe JC Jr, Harris RL, Garland B, et al. Candida osteomyelitis. Report of five cases and review of the literature. Am J Med 1987; 82:927.</a></li><li><a class="nounderline abstract_t">Hendrickx L, Van Wijngaerden E, Samson I, Peetermans WE. Candidal vertebral osteomyelitis: report of 6 patients, and a review. Clin Infect Dis 2001; 32:527.</a></li><li><a class="nounderline abstract_t">Gamaletsou MN, Rammaert B, Brause B, et al. Osteoarticular Mycoses. Clin Microbiol Rev 2022; 35:e0008619.</a></li><li><a class="nounderline abstract_t">Tunkel AR, Thomas CY, Wispelwey B. Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature. Am J Med 1993; 94:100.</a></li><li><a class="nounderline abstract_t">Brooks DH, Pupparo F. Successful salvage of a primary total knee arthroplasty infected with Candida parapsilosis. J Arthroplasty 1998; 13:707.</a></li><li><a class="nounderline abstract_t">Malani PN, McNeil SA, Bradley SF, Kauffman CA. Candida albicans sternal wound infections: a chronic and recurrent complication of median sternotomy. Clin Infect Dis 2002; 35:1316.</a></li><li><a class="nounderline abstract_t">Bisbe J, Miro JM, Latorre X, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis 1992; 15:910.</a></li><li><a class="nounderline abstract_t">Garbino J, Schnyder I, Lew D, et al. An unusual cause of vertebral osteomyelitis: Candida species. Scand J Infect Dis 2003; 35:288.</a></li><li><a class="nounderline abstract_t">Arias F, Mata-Essayag S, Landaeta ME, et al. Candida albicans osteomyelitis: case report and literature review. Int J Infect Dis 2004; 8:307.</a></li><li><a class="nounderline abstract_t">Slenker AK, Keith SW, Horn DL. Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. Diagn Microbiol Infect Dis 2012; 73:89.</a></li><li><a class="nounderline abstract_t">Neofytos D, Huprikar S, Reboli A, et al. Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry. Eur J Clin Microbiol Infect Dis 2014; 33:135.</a></li><li><a class="nounderline abstract_t">Evdoridou J, Roilides E, Bibashi E, Kremenopoulos G. Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Infection 1997; 25:112.</a></li><li><a class="nounderline abstract_t">Phelan DM, Osmon DR, Keating MR, Hanssen AD. Delayed reimplantation arthroplasty for candidal prosthetic joint infection: a report of 4 cases and review of the literature. Clin Infect Dis 2002; 34:930.</a></li><li><a class="nounderline abstract_t">Gamaletsou MN, Rammaert B, Bueno MA, et al. Candida Arthritis: Analysis of 112 Pediatric and Adult Cases. Open Forum Infect Dis 2016; 3:ofv207.</a></li><li><a class="nounderline abstract_t">O'Meeghan T, Varcoe R, Thomas M, Ellis-Pegler R. Fluconazole concentration in joint fluid during successful treatment of Candida albicans septic arthritis. J Antimicrob Chemother 1990; 26:601.</a></li><li><a class="nounderline abstract_t">Pérez-Gómez A, Prieto A, Torresano M, et al. Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 1998; 27:226.</a></li><li><a class="nounderline abstract_t">Fischman AJ, Alpert NM, Livni E, et al. Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother 1993; 37:1270.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Sim JP, Kho BC, Liu HS, et al. Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. Hong Kong Med J 2005; 11:120.</a></li><li><a class="nounderline abstract_t">Harris MC, Pereira GR, Myers MD, et al. Candidal arthritis in infants previously treated for systemic candidiasis during the newborn period: report of three cases. Pediatr Emerg Care 2000; 16:249.</a></li><li><a class="nounderline abstract_t">Weigl JA. Candida arthritis in a premature infant treated successfully with oral fluconazole for six months. Ann Acad Med Singapore 2000; 29:253.</a></li><li><a class="nounderline abstract_t">Dutronc H, Dauchy FA, Cazanave C, et al. Candida prosthetic infections: case series and literature review. Scand J Infect Dis 2010; 42:890.</a></li><li><a class="nounderline abstract_t">Anagnostakos K, Kelm J, Schmitt E, Jung J. Fungal periprosthetic hip and knee joint infections clinical experience with a 2-stage treatment protocol. J Arthroplasty 2012; 27:293.</a></li><li><a class="nounderline abstract_t">Ueng SW, Lee CY, Hu CC, et al. What is the success of treatment of hip and knee candidal periprosthetic joint infection? Clin Orthop Relat Res 2013; 471:3002.</a></li><li><a class="nounderline abstract_t">Merrer J, Dupont B, Nieszkowska A, et al. Candida albicans prosthetic arthritis treated with fluconazole alone. J Infect 2001; 42:208.</a></li><li><a class="nounderline abstract_t">Escolà-Vergé L, Rodríguez-Pardo D, Corona PS, Pigrau C. Candida Periprosthetic Joint Infection: Is It Curable? Antibiotics (Basel) 2021; 10.</a></li><li><a class="nounderline abstract_t">Hennequin C, Bourée P, Hiesse C, et al. Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature. Clin Infect Dis 1996; 23:176.</a></li><li><a class="nounderline abstract_t">Legout L, Assal M, Rohner P, et al. Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient. Scand J Infect Dis 2006; 38:728.</a></li><li><a class="nounderline abstract_t">Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60:363.</a></li><li><a class="nounderline abstract_t">Schilling A, Seibold M, Mansmann V, Gleissner B. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy. Med Mycol 2008; 46:79.</a></li><li><a class="nounderline abstract_t">Rössel P, Schønheyder HC, Nielsen H. Fluconazole therapy in Candida albicans spondylodiscitis. Scand J Infect Dis 1998; 30:527.</a></li><li><a class="nounderline abstract_t">Yang SC, Shao PL, Hsueh PR, et al. Successful treatment of Candida tropicalis arthritis, osteomyelitis and costochondritis with caspofungin and fluconazole in a recipient of bone marrow transplantation. Acta Paediatr 2006; 95:629.</a></li><li><a class="nounderline abstract_t">Pemán J, Jarque I, Bosch M, et al. Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns. J Clin Microbiol 2006; 44:1912.</a></li><li><a class="nounderline abstract_t">Sili U, Yilmaz M, Ferhanoglu B, Mert A. Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole. Clin Infect Dis 2007; 45:897.</a></li></ol></div><div id="topicVersionRevision">Topic 2466 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559466" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fungal Infections of the Bones and Joints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11462190" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vertebral osteomyelitis due to Candida species: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11243760" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Candida glabrata infection after total hip arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10524556" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Candida glabrata arthritis: case report and review of the literature of Candida arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Spinal osteomyelitis caused by Candida glabrata: case report and review</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7803635" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Candida tropicalis vertebral osteomyelitis: a late sequela of fungemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9108187" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22911646" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1616344" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fungal arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3555067" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Candida osteomyelitis. Report of five cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181113" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Candidal vertebral osteomyelitis: report of 6 patients, and a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36448782" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Osteoarticular Mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420285" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9741450" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Successful salvage of a primary total knee arthroplasty infected with Candida parapsilosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12439793" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Candida albicans sternal wound infections: a chronic and recurrent complication of median sternotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1457662" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12839165" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : An unusual cause of vertebral osteomyelitis: Candida species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15325600" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Candida albicans osteomyelitis: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22578942" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23907587" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance®registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9108188" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11880958" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Delayed reimplantation arthroplasty for candidal prosthetic joint infection: a report of 4 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26858961" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Candida Arthritis: Analysis of 112 Pediatric and Adult Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2254231" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fluconazole concentration in joint fluid during successful treatment of Candida albicans septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9514128" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Role of the new azoles in the treatment of fungal osteoarticular infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8328777" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15815067" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966343" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Candidal arthritis in infants previously treated for systemic candidiasis during the newborn period: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10895350" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Candida arthritis in a premature infant treated successfully with oral fluconazole for six months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20608769" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Candida prosthetic infections: case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752583" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fungal periprosthetic hip and knee joint infections clinical experience with a 2-stage treatment protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633184" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : What is the success of treatment of hip and knee candidal periprosthetic joint infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11545555" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Candida albicans prosthetic arthritis treated with fluconazole alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33920619" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Candida Periprosthetic Joint Infection: Is It Curable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8816150" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16857628" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17526917" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Caspofungin for the treatment of less common forms of invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17852716" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10066061" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fluconazole therapy in Candida albicans spondylodiscitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16825152" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Successful treatment of Candida tropicalis arthritis, osteomyelitis and costochondritis with caspofungin and fluconazole in a recipient of bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672439" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17806057" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
